MedTrace Logo

Addition of Spironolactone in Patients With Resistant Arterial Hypertension

NCT00524615 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2012-06-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of spironolactone on lowering blood pressure when added to therapy in patients with resistant arterial hypertension.

Conditions

Interventions

DRUG

spironolactone

25 mg of spironolactone once daily or placebo for 2 months

Sponsors & Collaborators

  • Czech Society of Hypertension

    collaborator OTHER

  • Prostejov Hospital

    collaborator UNKNOWN

  • Brno University Hospital

    collaborator OTHER

  • Olomouc Military Hospital

    collaborator UNKNOWN

  • Gedeon Richter Ltd.

    collaborator INDUSTRY

  • Jan Vaclavík

    lead OTHER

Principal Investigators

  • Jan Václavík, MD. · Internal medicine department I, Olomouc university hospital and Palacký University School of medicine

  • Bořek Lačňák, MD. · Internal Medicine Dept., Šternberk Hospital

  • Martin Plachý, MD. · Internal medicine department II, Brno University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2012-10-31
Completion
2012-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00524615 on ClinicalTrials.gov